Earnings summaries and quarterly performance for CDXC.
Research analysts who have asked questions during CDXC earnings calls.
SM
Sean McGowan
ROTH Capital Partners
4 questions for CDXC
Also covers: CELH, FTLF, GRPN +8 more
Bill Dezellem
Tieton Capital Management
3 questions for CDXC
Also covers: ACIC, ADTN, AP +12 more
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
1 question for CDXC
Also covers: ANGO, BLFS, CODX +8 more
JM
Jan Mark
[indiscernible] Research
1 question for CDXC
M[
Mitchell [Analyst]
H.C. Wainwright
1 question for CDXC
MP
Mitchell Pinheiro
Sturdivant & Company
1 question for CDXC
Also covers: CVGW, FDP, FLO +4 more
MP
Mitch Pinheiro
Sturdivant & Co.
1 question for CDXC
Also covers: CVGW
RS
Ram Selvaraju
H.C. Wainwright
1 question for CDXC
Also covers: ABEO, ADXN, BCPC +8 more
Susan Anderson
Canaccord Genuity Group
1 question for CDXC
Also covers: BODI, COTY, ELF +13 more
William Dezellem
Tieton Capital Management
1 question for CDXC
Also covers: ACIC, ADTN, BGSF +15 more
Recent press releases and 8-K filings for CDXC.
Niagen Bioscience Discusses Financials and Growth Strategy
CDXC
New Projects/Investments
Share Buyback
Revenue Acceleration/Inflection
- Niagen Bioscience (formerly ChromaDex) reported strong financial performance for the last 12 months, with approximately $125 million in revenue and $20 million in net income, maintaining a cash balance of just under $65 million and no debt.
- The company is expanding its market presence with Niagen Plus (IV/injection products), which generated $50 million-$100 million in retail sales in its first year, and plans to launch a direct-to-consumer telehealth business for home injection kits later in 2026.
- Significant growth opportunities are being pursued in the pharmaceutical sector for orphan diseases and the skincare market, with announcements expected in the skincare space in 2026.
- Niagen Bioscience operates with a conservative capital strategy, holding a strong cash position, actively evaluating acquisition opportunities, and intending to utilize its share buyback program.
Jan 15, 2026, 4:30 PM
Niagen Bioscience Discusses Strategic Growth and Financial Performance
CDXC
New Projects/Investments
Share Buyback
Revenue Acceleration/Inflection
- Niagen Bioscience, formerly ChromaDex, focuses on its primary product, Niagen (nicotinamide riboside), which is a precursor to NAD, supported by over 100 patents and extensive R&D with 41 clinical studies and over 100 preclinical studies published on Niagen.
- For the last 12 months, the company reported approximately $125 million of revenue and $20 million of net income, maintaining a strong balance sheet with just under $65 million of cash and no debt.
- The company is expanding its business verticals, including IV and injection products, and plans to launch its own telehealth business for at-home injections later in 2026. It is also pursuing opportunities in orphan diseases and the skincare market, with announcements expected in the skincare space in 2026.
- Niagen Bioscience operates with a conservative financial approach, prioritizing cash, and has a share buyback program in place, which it intends to use under set parameters.
Jan 15, 2026, 4:30 PM
Niagen Bioscience Discusses Financial Performance and Strategic Growth
CDXC
New Projects/Investments
Share Buyback
Revenue Acceleration/Inflection
- Niagen Bioscience (formerly ChromaDex) reported approximately $125 million of revenue and $20 million of net income for the last 12 months, maintaining a strong balance sheet with just under $65 million of cash and no debt.
- The company is expanding its product offerings to include Niagen Plus (IV/injection products) and plans to launch a direct-to-consumer telehealth business for home injection kits later in 2026.
- Strategic growth initiatives for 2026 include aggressively pursuing the skincare market and exploring pharmaceutical applications for orphan diseases, alongside a partnership with a network of 7,000-8,000 medical practitioners.
- A share buyback program was announced a few months prior and is intended to be utilized.
Jan 15, 2026, 4:30 PM
Niagen Biosciences Reports Record Q3 2025 Results and Raises Full-Year Revenue Guidance
CDXC
Earnings
Guidance Update
Product Launch
- Niagen Biosciences delivered record performance in the third quarter of 2025, with $34 million in revenue, a 33% increase year-over-year, and a net income of $4.6 million. The company ended the quarter with $64.3 million in cash and no debt.
- Key revenue drivers included e-commerce net sales of $19 million, a 29% increase year-over-year, and the distribution business which grew 109% year-over-year to $7 million. Tru Niagen revenue specifically grew 44% to $26 million.
- The company revised its full-year 2025 revenue growth guidance upwards from 22-27% to 25-30% year-over-year.
- Niagen Biosciences launched Niagen Plus at-home injection kits in August and has onboarded more than 1,000 wellness and healthcare clinics across the United States to offer its Niagen Plus product line.
- The FDA reversed a prior determination that nicotinamide mononucleotide (NMN) could not be lawfully marketed as a dietary supplement, though Niagen Biosciences believes this decision will face strong opposition and notes that many NMN products on the market do not meet label claims and may infringe on existing patents.
Nov 4, 2025, 9:30 PM
Quarterly earnings call transcripts for CDXC.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more